EUVIMEDEUVIMED entdecken
Open Access

Association of Obesity and Innate Immune Markers With Resistance to Biologic Therapy in Psoriasis

Hee Joo Kim, Eun-Hui Lee, YunJae Jung

JAMA Dermatology · 01.06.2025 · 161 (6) · 629

DOI: 10.1001/jamadermatol.2025.0288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.06.2025. Verfasst von Hee Joo Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea. Hauptthemen laut MEDLINE: Psoriasis, Biological Products, Obesity, Immunity, Innate. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Currently available biologics specifically target dermal adaptive immune molecules, such as interleukin (IL)-17 and IL-23, which are crucial in the pathogenesis of psoriasis. Despite their remarkably enhanced therapeutic effects compared with those of traditional anti-inflammatory systemic medications, 25% to 50% of patients are still resistant to biologic therapy.

Objective

To delineate the inflammatory microenvironmental factors that affect sustained treatment response in patients with severe psoriasis. Design, Setting, and Participants A cross-sectional study was carried out including patients aged 18 years or older who visited the Gachon University Gil Medical Center dermatology clinic between January 2012 and December 2022 with plaque-type severe psoriasis with a Psoriasis Area and Severity Index score greater than 10 and body surface area larger than 10 despite conventional treatment with cyclosporine, methotrexate, acitretin, and phototherapy for longer than 3 months, and treatment with biologics for at least 24 months. Analysis was carried out from December 2023 to September 2024. Main Outcome and Measure Clinical and inflammatory factors associated with sustained response to biologics therapy.

Results

Among the 87 patients (mean [SD] age, 42.2 [12.5] years; 24 female patients and 63 male patients) included in the study, 16 (18.4%) had to switch to other biologics because of an early loss of therapeutic efficacy. Having overweight (body mass index, >25) was the only clinically relevant factor (odds ratio, 17.3; 95% CI, 3.2-434.6; P = .009). Other factors, including initial disease severity before biologics or disease duration until the first use of biologics, were not different between patients with treatment-resistant disease and those with a sustained treatment response. Spatial transcriptomics pathway analyses revealed enriched innate immune signaling and T-helper 17 cells (Th17)/IL-17 signaling pathways, with upregulated expression of innate immune- or neutrophil-related genes, such as TNFSF10 , CXCL8 , LCN2 , S100A8 , and S100A9 , mainly in the epidermis. Enriched ligand-receptor interactions were observed in the IL-36 family of cytokines, antimicrobial peptides, and tumor necrosis factor (TNF) signaling. Immunofluorescence analysis showed enhanced protein expression of lipocalin 2, S100A8/A9, IL-36α, IL-36γ, IL-1RA, and TNF-related apoptosis-inducing ligand (TRAIL) in the epidermis. Conclusions and Relevance This cross-sectional study found that dysregulated innate immune responses in the epidermis and heightened neutrophil activity may be responsible for decreased sustainability of therapeutic responses to biologics. Given that current biologics mainly target dermal adaptive immune-related mediators, the development of novel therapeutic strategies to target the epidermal innate immune response, including neutrophils, is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological ProductsObesityImmunity, InnateDrug ResistanceBiological TherapyDermatologic AgentsHumansMaleFemaleAdultCross-Sectional StudiesMiddle AgedSeverity of Illness IndexBiomarkersTreatment Outcome

Substanzen

Biological ProductsBiomarkersDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea.
  • Lee Gil Ya Cancer and Diabetes Institute, Gachon University College of Medicine, Incheon, South Korea.
  • Department of Microbiology, Gachon University College of Medicine, Incheon, South Korea.
  • Department of Health Science and Technology, Gachon Advanced Institute for Health Science & Technology, Gachon University, Incheon, South Korea.

Zitieren

APA

Kim, H. J., Lee, E. H., & Jung, Y. (2025). Association of Obesity and Innate Immune Markers With Resistance to Biologic Therapy in Psoriasis. JAMA Dermatology, 161(6), 629. https://doi.org/10.1001/jamadermatol.2025.0288

Vancouver

Kim HJ, Lee EH, Jung Y. Association of Obesity and Innate Immune Markers With Resistance to Biologic Therapy in Psoriasis. JAMA Dermatology. 2025;161(6):629. doi:10.1001/jamadermatol.2025.0288

BibTeX
@article{Kim2025,
  author = {Kim, Hee Joo and Lee, Eun-Hui and Jung, YunJae},
  title = {Association of Obesity and Innate Immune Markers With Resistance to Biologic Therapy in Psoriasis},
  journal = {JAMA Dermatology},
  year = {2025},
  volume = {161},
  number = {6},
  pages = {629},
  doi = {10.1001/jamadermatol.2025.0288}
}
Kostenlos starten →